NASDAQ:CARACara Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cara Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $17.43 +0.21 (+1.22 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$16.72Now: $17.43▼$19.1350-Day Range$16.44MA: $17.31▼$17.9252-Week Range$8.88Now: $17.43▼$26.67Volume983,800 shsAverage Volume518,986 shsMarket Capitalization$815.65 millionP/E RatioN/ADividend YieldN/ABeta1.81 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that is in Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; and in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.50, Cara Therapeutics has a potential upside of 97.9% from its current price of $17.43.Amount of Analyst CoverageCara Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.2 Community Rank Outperform VotesCara Therapeutics has received 636 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCara Therapeutics has received 365 “underperform” votes. (Add your “underperform” vote.)Community SentimentCara Therapeutics has received 63.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote “Outperform” if you believe CARA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $366,665.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions68.79% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cara Therapeutics are expected to grow in the coming year, from ($2.57) to ($2.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -6.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -6.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 3.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.67 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CARA Previous Symbol CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone203-406-3700Debt Debt-to-Equity Ratio0.02 Current Ratio4.07 Quick Ratio4.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$19.89 million Price / Sales41.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.66 per share Price / Book3.74Profitability EPS (Most Recent Fiscal Year)($2.49) Net Income$-106,370,000.00 Net Margins-480.55% Return on Equity-61.95% Return on Assets-49.98%Miscellaneous Employees55 Outstanding Shares46,796,000Market Cap$815.65 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $17.43 +0.21 (+1.22 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CARA News and Ratings via Email Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter. Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions How has Cara Therapeutics' stock been impacted by Coronavirus (COVID-19)? Cara Therapeutics' stock was trading at $13.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CARA stock has increased by 29.8% and is now trading at $17.43. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cara Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cara Therapeutics. When is Cara Therapeutics' next earnings date? Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Cara Therapeutics. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics Inc (NASDAQ:CARA) posted its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.68) by $0.14. Cara Therapeutics had a negative return on equity of 61.95% and a negative net margin of 480.55%. View Cara Therapeutics' earnings history. What price target have analysts set for CARA? 4 analysts have issued 1 year target prices for Cara Therapeutics' stock. Their forecasts range from $30.00 to $40.00. On average, they expect Cara Therapeutics' share price to reach $34.50 in the next twelve months. This suggests a possible upside of 97.9% from the stock's current price. View analysts' price targets for Cara Therapeutics. Has Cara Therapeutics been receiving favorable news coverage? News coverage about CARA stock has trended extremely negative this week, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cara Therapeutics earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news about Cara Therapeutics. Who are some of Cara Therapeutics' key competitors? Some companies that are related to Cara Therapeutics include Opko Health (OPK), Insmed (INSM), Axsome Therapeutics (AXSM), Alkermes (ALKS), Agios Pharmaceuticals (AGIO), Principia Biopharma (PRNB), CytoDyn (CYDY), SAGE Therapeutics (SAGE), Amarin (AMRN), Deciphera Pharmaceuticals (DCPH), Pacira Biosciences (PCRX), Taro Pharmaceutical Industries (TARO), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX) and Apellis Pharmaceuticals (APLS). View all competitors. What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Canopy Growth (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals PLC- (GWPH), 22nd Century Group (XXII), Insys Therapeutics (INSY), Novavax (NVAX), Fate Therapeutics (FATE) and BioMarin Pharmaceutical (BMRN). Who are Cara Therapeutics' key executives? Cara Therapeutics' management team includes the following people: Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 55)Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 53)Dr. Joana Goncalves, Chief Medical Officer (Age 45)Dr. Joseph Stauffer, Consultant (Age 53)Dr. Michael E. Lewis, Co-Founder & Chief Scientific Advisor (Age 67) What is Cara Therapeutics' stock symbol? Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA." Who are Cara Therapeutics' major shareholders? Cara Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include RHO Capital Partners Inc. (5.98%), Goldman Sachs Group Inc. (0.69%), Bank of New York Mellon Corp (0.39%), SG Americas Securities LLC (0.25%), Swiss National Bank (0.21%) and California Public Employees Retirement System (0.18%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View institutional ownership trends for Cara Therapeutics. Which major investors are selling Cara Therapeutics stock? CARA stock was sold by a variety of institutional investors in the last quarter, including RHO Capital Partners Inc., UBS Group AG, California Public Employees Retirement System, and Commonwealth Equity Services LLC. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, and Scott Terrillion. View insider buying and selling activity for Cara Therapeutics. Which major investors are buying Cara Therapeutics stock? CARA stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., SG Americas Securities LLC, Aigen Investment Management LP, WINTON GROUP Ltd, Russell Investments Group Ltd., Swiss National Bank, ProShare Advisors LLC, and Arizona State Retirement System. View insider buying and selling activity for Cara Therapeutics. How do I buy shares of Cara Therapeutics? Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cara Therapeutics' stock price today? One share of CARA stock can currently be purchased for approximately $17.43. How big of a company is Cara Therapeutics? Cara Therapeutics has a market capitalization of $815.65 million and generates $19.89 million in revenue each year. The biopharmaceutical company earns $-106,370,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe. What is Cara Therapeutics' official website? The official website for Cara Therapeutics is www.caratherapeutics.com. How can I contact Cara Therapeutics? Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700. This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
